NovoCure (NASDAQ:NVCR) Stock Price Down 7.7% on Insider Selling

NovoCure Limited (NASDAQ:NVCR) was down 7.7% during mid-day trading on Friday after an insider sold shares in the company. The stock traded as low as $13.19 and last traded at $13.1290. Approximately 445,392 shares traded hands during trading, a decline of 80% from the average daily volume of 2,190,604 shares. The stock had previously closed at $14.23.

Specifically, Chairman William F. Doyle sold 71,887 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total transaction of $933,093.26. Following the completion of the transaction, the chairman directly owned 328,397 shares of the company’s stock, valued at $4,262,593.06. This represents a 17.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Mukund Paravasthu sold 43,246 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $13.77, for a total value of $595,497.42. Following the transaction, the chief operating officer owned 72,832 shares in the company, valued at $1,002,896.64. The trade was a 37.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In related news, COO Mukund Paravasthu sold 5,377 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $71,567.87. Following the transaction, the chief operating officer owned 116,078 shares of the company’s stock, valued at $1,544,998.18. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NVCR. Wedbush reissued a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a report on Thursday, January 15th. Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. HC Wainwright lifted their price target on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $26.93.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Quarterly results showed an EPS beat and revenue growth (year-over-year revenue +8.2%), which supports fundamentals and was cited by analysts when updating models. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive: HC Wainwright raised its price target and several analysts maintain Buy ratings or higher targets, providing upside cases versus the current share price. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerages’ consensus rating is “Hold,” indicating limited near‑term conviction for a re‑rating; consensus target remains well above the current price, which creates a mixed signal for investors. NovoCure receives average “Hold” rating
• Neutral Sentiment: Institutional ownership is high (reported ~84.6%), which can reduce free‑float volatility but also means insider moves may attract outsized attention. Institutional holdings (MarketBeat)
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k at ~$12.98), trimming his stake by ~18% — a sizable single insider sale that the market interprets as a negative signal. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO, CEO, CFO and other insiders) executed notable sales over the same period — a pattern that amplifies negative sentiment and likely pressured the stock intraday. Aggregated filings and coverage of these insider transactions are available. Insider trades summary (MarketBeat)

NovoCure Stock Down 7.5%

The company has a current ratio of 2.90, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $12.75 and a 200 day moving average of $12.71. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -10.79 and a beta of 0.71.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.19. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The company had revenue of $174.35 million during the quarter, compared to the consensus estimate of $174.40 million. During the same period last year, the firm earned ($0.61) earnings per share. The company’s revenue was up 8.2% on a year-over-year basis. On average, sell-side analysts anticipate that NovoCure Limited will post -1.3 earnings per share for the current year.

Institutional Trading of NovoCure

Institutional investors and hedge funds have recently bought and sold shares of the company. Kera Capital Partners Inc. boosted its holdings in shares of NovoCure by 84.4% during the fourth quarter. Kera Capital Partners Inc. now owns 19,691 shares of the medical equipment provider’s stock valued at $244,000 after acquiring an additional 9,015 shares during the period. Corient Private Wealth LLC grew its position in NovoCure by 178.0% in the 4th quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock worth $1,259,000 after purchasing an additional 62,341 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of NovoCure by 14.5% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock valued at $422,000 after purchasing an additional 4,124 shares during the period. Empowered Funds LLC bought a new stake in shares of NovoCure during the fourth quarter valued at approximately $33,000. Finally, XTX Topco Ltd boosted its position in shares of NovoCure by 159.2% during the fourth quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after buying an additional 36,111 shares during the period. Institutional investors and hedge funds own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.